Understanding the Impact of Cytogenetic Abnormalities in Acute Myeloid Leukemia

At the completion of this activity, the participant will be able to:
1. Classify patients with AML as favorable, intermediate, or adverse risk based on genetic abnormalities.
2. Identify molecular mutations that influence a patient’s likelihood of response to chemotherapy.
3. Discuss the available literature for FMS-like tyrosine kinase 3 (FLT3) mutations and targeted medications.
4. Summarize the available literature for medications targeted against isocitrate dehydrogenase (IDH) 1 and 2 mutations.